CJC + Ipamorelin 10mg vial

GH secretagogues

What is CJC-1295 + Ipamorelin?

Last updated: 29 October 2026

A GHRH analogue paired with a selective ghrelin-receptor agonist, studied in growth-hormone axis research.

GHRH + GH secretagoguePreclinical / early clinical
Class
GHRH analogue + GH secretagogue
Also known as
Mod GRF(1–29) + ipamorelin
Type
Two-peptide blend
Research stage
Preclinical / early clinical

01 · Classification

What it is

This blend combines two peptides that act on different parts of the growth-hormone axis. CJC-1295 without DAC (also called modified GRF 1–29) is a stabilised version of the first 29 amino acids of growth-hormone-releasing hormone. Ipamorelin is a five-amino-acid peptide that activates the ghrelin receptor.

They are paired in research because GHRH-type and ghrelin-type signals act through separate receptors and are studied for combined effects on GH pulses.

02 · Mechanisms

What has been studied

  • GHRH receptor: the CJC-1295 component acts on pituitary GHRH receptors.
  • GHS-R1a (ghrelin receptor): ipamorelin is described as selective, with little effect on cortisol or prolactin in early studies.
  • Pulsatility: research focuses on how each component shapes the timing and size of GH release.

03 · Evidence

Where the research is

Each component has limited early-phase clinical data. The combination itself has little published controlled research.

04 · Primary sources

Read the literature

Search the primary research record directly rather than relying on summaries, including this one.

Research use only

Supplied strictly for laboratory and educational research. Not a medicinal product, not for human or veterinary use, and not evaluated by any medicines regulator. This overview is not medical advice and gives no dosing or administration guidance.

← All research overviews